

***IFIH1* loss-of-function predisposes to inflammatory and SARS-CoV-2-related infectious diseases**

Rania Najm¹, Lemis Yavuz², Ruchi Jain³, Maha El Naofal³, Sathishkumar Ramaswamy³, Walid Abuhammour², Tom Loney¹, Norbert Nowotny^{1,4}, Alawi Alsheikh-Ali^{1,5}, Ahmad Abou Tayoun^{1,3} and Richard K. Kandasamy^{6,7}

¹College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates

²Al Jalila Children's Hospital, Dubai, United Arab Emirates

³Al Jalila Genomics Center, Al Jalila Children's Hospital, Dubai, United Arab Emirates

⁴Institute of Virology, University of Veterinary Medicine Vienna, Vienna, Austria

⁵Dubai Academic Health Corporation, Dubai, United Arab Emirates

⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, United States

⁷Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota 55905, United States

Correspondence to: Ahmad.Tayoun@ajch.ae or Kandasamy.RichardKumaran@mayo.edu

Abstract

The *IFIH1* gene, encoding melanoma differentiation-associated protein 5 (MDA5), is an indispensable innate immune regulator involved in the early detection of viral infections. Previous studies described MDA5 dysregulation linking it to weakened immunological responses, and increased susceptibility to microbial infections and autoimmune disorders. Monoallelic gain-of-function of the *IFIH1* gene has been associated with multisystem disorders, namely Aicardi-Goutieres and Singleton-Merten syndromes, while biallelic loss of this gene causes immunodeficiency. In this study, nine patients suffering from different cases of recurrent infections, inflammatory diseases, severe COVID-19, or multisystem inflammatory syndrome in children (MIS-C) were identified with putative loss-of-function *IFIH1* variants by whole exome sequencing. All patients revealed signs of lymphopenia and an increase in inflammatory markers, including CRP, amyloid A, ferritin, and IL-6. One patient with a pathogenic homozygous variant c.2807+1G>A was the most severe case showing immunodeficiency and glomerulonephritis. The c.1641+1G>C variant was identified in the heterozygous state in patients suffering from periodic fever, COVID-19, or

MIS-C, while the c.2016delA variant was identified in two patients with inflammatory bowel disease or MIS-C. Expression analysis showed that PBMCs of one patient with a c.2016delA variant had a significant decrease in *ISG15*, *IFNA* and *IFNG* transcript levels, compared to normal PBMCs, upon stimulation with poly(I:C), suggesting that MDA5 receptor truncation disrupts the immune response. Our findings accentuate the implication of rare monogenic *IFIH1* loss-of-function variants in altering the immune response, and severely predisposing patients to inflammatory and infectious diseases, including SARS-CoV-2 related disorders.

Introduction

The melanoma differentiation-associated protein 5, MDA5, is a critical element of the innate immune system and is essential for the detection of viral infections. MDA5 is encoded by the *IFIH1* gene and belongs to RIG-I-like receptors (RLRs) that recognizes viral double stranded RNA in the cytoplasm of infected cells. Two N-terminal caspase activation and recruitment domains (CARDs), followed by a helicase, Pincer, and C-terminal domain-like regions (CTD), make up the structure of MDA5. The helicase domain includes RecA-like domains, namely Hel1 and Hel2, and possess ATPase activity needed to unwind double-stranded RNA complexes. The Pincer domain is responsible for the ATPase core activation and structural support, whereas CTD is for dsRNA binding¹⁻³. Upon MDA5 activation, the receptor oligomerizes and interact with the mitochondrial anti-viral-signaling protein (MAVS), an adaptor for RLR signal transduction pathway. This is followed by the activation of interferon regulatory factor 3/7 (IRF3/IRF7) and NF- κ B transcription factors; hence, inducing the expression of type I and III interferon (IFN) genes^{2,4}. Paracrine and autocrine IFN stimulation induce IFN-stimulated genes (ISGs) that are needed for an antimicrobial response^{1,5,6}. This allows the establishment of an antiviral state in the neighbouring cell and regulation of immune cells activation to efficiently mount an antiviral immune response.

Mutations in *IFIH1* have been associated with auto-inflammatory disorders and vulnerability to a wide range of viral infections. Previous studies showed that heterozygous gain-of-function *IFIH1* variants cause a spectrum of auto-inflammatory pathologies including Aicardi-Goutieres syndrome type 7^{7,8}, Singleton-Merten syndrome 1⁹, and IgA deficient systemic lupus erythematosus¹⁰. The immune-pathologies result from the constitutive or aberrant activation of MDA5 with an enhanced sensitivity to self-derived nucleic acid¹¹. Consequently, *IFIH1* gain-of-function variants cause an autoinflammatory state of type I interferonopathy via an enhanced or constitutively active downstream MAVS pathway¹².

Nevertheless, *IFIH1* loss-of-function variants increased susceptibility to viral and frequent severe respiratory tract infections by drastically impairing the immune response¹³⁻¹⁵. Furthermore, autoimmune and immune-mediated diseases such as multiple sclerosis¹⁶, type 1 diabetes¹⁷, sclerosing cholangitis^{18,19} and very early onset inflammatory bowel disease²⁰ have been linked to *IFIH1* loss-of-function. The mechanism behind the development of severe disorders by these risk alleles is yet to be elucidated; however, type I interferon dysregulation may highly contribute to susceptibility to infections and in the initiation of autoinflammatory/autoimmune responses¹.

We have previously shown that *IFIH1* loss-of-function variants are significantly enriched in patients with high susceptibility to infections²¹. Furthermore, transcriptomic analysis of patients with COVID-19 showed that *IFIH1* expression is significantly altered in this group of patients relative to controls²². We therefore hypothesized that *IFIH1* regulates common immune-related pathways which, when altered, can increase predisposition to infections such as SARS-CoV-2.

Materials and Methods

Study Cohort

Patients presenting with recurrent infections and/or inflammatory disease were found, by clinical genomic testing, to carry loss-of-function variants in the *IFIH1* gene were included in this study (N = 5). In addition, patients meeting criteria for severe COVID-19²³ or MIS-C²⁴ and subsequently determined to have loss-of-function *IFIH1* variants by whole exome sequencing, were also included (N = 4). This study was approved by the Dubai Scientific Research Ethics Committee-Dubai Health Authority (Study numbers: DSREC-07/2023_06, DSREC-SR-03/2023_08, and DSREC-07/2021_05).

Clinical and Demographic Information

Deidentified patient information was extracted from electronic medical records at Al Jalila Children's Hospital or Rashid Hospital (Dubai, United Arab Emirates) where those patients were treated and/or recruited for the study. Data was collected on standardized data collection form. Variables included demographic information, clinical manifestation, blood workup results, severity of the disease, course of illness, diagnosis, treatment, and outcome. After

reviewing and evaluating all information, common variables and abnormal results among the patients were highlighted as presented below.

Genomic Sequencing

Whole exome sequencing was performed as previously described²⁵. Briefly, after DNA extraction and fragmentation, coding regions were enriched using the Agilent Clinical Research Exome V2 (CREv2) capture probes (Agilent, USA) and subsequently sequenced (2 × 150 bp) using the NovaSeq system (Illumina, USA) to a minimum average depth of 100X.

Bioinformatic Analysis

Sequencing data were then processed using an in-house, custom-made bioinformatics pipeline to retain high-quality sequencing reads across all coding regions, and prioritize high-quality variants after annotating with allele frequency (using mainly the Genome Aggregation database, the Greater Middle East variome database, and the Middle East Variation (MEV) database)²⁶, predicted protein effects, and presence or absence in disease databases, such as ClinVar and the Human Gene Mutation database (HGMD). All variants reported in the *IFIH1* gene were according to the transcript number: NM_022168.3. Loss-of-function enrichment analysis was performed as previously described²¹.

PBMC Isolation and Treatment

Peripheral blood was obtained from a healthy volunteer and patient #4 with the heterozygous c.2016delA *IFIH1* variant. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized peripheral blood using Histopaque-1077 (Sigma) by density centrifugation. Normal PBMCs (nPBMC) and patient 4 PBMCs (P4 PBMC) were rested for 24 hours in RPMI-1640 (Gibco) supplemented with 10% Fetal Bovine Serum (FBS) (Sigma) and antibiotics. For poly(I:C) transfection, 5×10^5 cells were seeded in 500ul of Opti-MEM (Gibco) in a 24-well plate. Cells were transfected with 10µg/ml of poly(I:C) using Lipofectamine 3000 Transfection Kit (Invitrogen) according to the manufacturer's protocols and stopped after 6, 10, and 24 hours for sample collection. Transfected cells without poly(I:C) and collected after 24 hours were used as negative control. Experiments were performed in 4 biological replicates.

Gene Expression Studies

Total RNA from normal or patient PBMCs treated or untreated with poly(I:C) was extracted by Trizol (Ambion, Life Technologies). cDNA was synthesized using a Reverse Transcription Kit (Qiagen, QuantiTect). SYBR Green RT-qPCR was carried out using the QuantStudio5 machine. Primer sequences are listed in Table S1. For RT-qPCR, individual reactions included 150ng of cDNA, 0.25 μ M of each primer, and PowerUp SYBR Green Master Mix in a final volume of 10 μ l. PCR reactions started with a DNA denaturation step (95°C, 3 minutes), followed by 40 cycles of denaturation (95°C, 15 seconds), annealing (57°C, 60 seconds), extension (72°C, 30 seconds). Reactions were conducted in duplicate for each experiment. For analysis, individual genes expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), a housekeeping gene (Table S1), and Livak method was used to calculate the transcript expression levels²⁷.

Results

Patient cohort

To further understand the role of *IFIH1* in predisposition to infections, we searched for loss-of-function variants in this gene in three patient cohorts: 1) 51 pediatric patients referred to clinical genomic testing for recurrent infections, periodic fever, immunodeficiency and/or inflammatory disease, 2) 45 patients meeting the criteria for MIS-C, and 3) 55 young (mean age 34 years) patients with severe COVID-19 who were otherwise healthy.

Identification of *IFIH1* loss-of-function variants

Whole exome sequencing was performed on all 151 patients (62% males) and analysis was restricted to predicted loss-of-function variants in the *IFIH1* gene. Such variants were identified in 9 patients, including two patients diagnosed with severe COVID-19, two patients with MIS-C, three patients with periodic fever, and two other patients presenting with immunodeficiency or inflammatory bowel disease (IBD) (**Table 1**). The same variant, c.1641+1G>C, was identified in 3 patients while the frameshift c.2016delA variant was identified in 2 other patients. Variants were heterozygous in 8 patients, while in patient 6, presenting with variable immunodeficiency and glomerulonephritis, the c.2807+1G>A was in the homozygous state.

We noticed at least a 5-fold enrichment of loss-of-function variant in the *IFIH1* gene in this combined cohort (N = 151) relative to healthy individuals of Middle Eastern origin (N = 990)

(10/302 or 3.3% vs 13/1981 or 0.66%; $p = 0.0003$, Fisher's exact test)²⁸. This observation confirms previous findings and further implicate a role for *IFIH1* in susceptibility to infections^{14,21}.

Table 1: List containing the gender, clinical presentation, *IFIH1* variant and *IFIH1* zygosity of patients included in this study.

Patient	Gender	Presentation	<i>IFIH1</i> variant	Zygosity
1	Male	Periodic fever	c.1641+1G>C; p.?	Heterozygous
2	Male	Periodic fever	c.1764delA; p.A589Lfs*16	Heterozygous
3	Male	Periodic fever	c.769+3A>G; p.?	Heterozygous
4	Male	MIS-C	c.2016delA; p.D673Ifs*5	Heterozygous
5	Male	MIS-C	c.1641+1G>C; p.?	Heterozygous
6	Male	Immunodeficiency with glomerulonephritis	c.2807+1G>A; p.?	Homozygous
7	Female	Inflammatory bowel disease (IBD)	c.2016delA; p.D673Ifs*5	Heterozygous
8	Male	Severe COVID-19	c.1641+1G>C; p.?	Heterozygous
9	Male	Severe COVID-19	c.2730C>A; p.Cys910*	Heterozygous

Clinical and Laboratory Characteristics of patients with *IFIH1* Loss-of-function

Most patients (median age: 9 years) were male (8/9 or 88.9%) and the majority were Arab descendants (8 Arabs and 1 Bangladeshi) (**Table 2**). Despite the small size of this *IFIH1* cohort, the sex distribution suggests a possible association between *IFIH1* variants and susceptibility to infections in males.

All 9 patients in this cohort presented with fever and signs of autoimmune or inflammatory disease. The initial clinical picture on presentation for each patient was suggestive of viral or bacterial infections, then the course of illness indicated immune system malfunction. Blood workup across this cohort revealed high inflammatory markers including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, and interleukin 6 (IL-6) (**Table 2**).

Increased Amyloid A in patients 1, 2, and 3 indicated a chronic inflammation that could be secondary to autoimmune or chronic infection²⁹ (**Table 2**). Glomerulonephritis in patient 6 and Inflammatory Bowel Disease in patient 7, both have immune-related or autoimmune backgrounds^{30,31}. Dysregulated immune response to SARS-CoV-2 in previously healthy patients led to hyperinflammation and cytokine storm in patients with severe COVID-19 (patients 8 and 9) or MIS-C (patients 4 and 5)³². All patients received immunosuppressive medication such as corticosteroids.

Table 2: Summary for the patients' demographic information (gender, background, and age) and blood workup results (absolute lymphocyte, CRP, ESR, Amyloid A, Ferritin, and IL-6). CRP: C-Reactive Protein, ESR: Erythrocyte Sedimentation Rate.

Gender	8/9 males
Ethnicity	8/9 Arabs
Age (yrs) Median (range)	9 (1.5-30)
Absolute Lymphocyte (4.00-9.00) 10(3)/μL Median (range), N	1.2 (0.5-5.6), 9
CRP (0-2.8 mg/dl) Median (range), N	123 (13-324), 8
ESR (<10) Median (range), N	53 (23-100), 5
Amyloid A (n<6.4 mg/L) Median (range), N	475 (263-486), 3
Ferritin (6-67 ng/ml) Median (range), N	393 (144-1750), 5
IL-6 (n< 7 pg/ml) Median (range), N	109 (32-1362), 3

Expression analysis

The role of homozygous c.2016delA;p.D673Ifs*5 MDA5 variant has been previously described in IBD²⁰. In our study, the heterozygous form is detected in two patients 4 and 7 diagnosed with MIS-C and IBD, respectively. The putative truncated MDA5 receptor resulting from c.2016delA variant may lack essential domains including, Hel2, Pincer, and CTD (**Fig. 1A**). Thus, to decipher the role of MDA5 receptor in the severity of infection with

SARS-CoV-2, cytokine and interferon gene transcript levels were evaluated in the PBMCs derived from patient #4. The screened cytokines included *IFNA*, *IFNB*, *IFNL1*, *IFNG*, *IL-6*, *IL-10* and *IL-1B* in addition to the interferon gene transcript *ISG15*, where only transcripts with significant variation are shown.

We used poly(I:C) to simulate RNA virus infection and studied its effect on truncated MDA5 activation in mononuclear cells. Since MDA5 is a cytoplasmic receptor, PBMCs isolated from a healthy individual and patient #4 were transfected with poly(I:C) for 6, 10 and 24 hours, to ensure delivery to the cytoplasm, or without poly(I:C) for 24 hours. Interestingly, *IFNA* transcript level significantly decreased by 82% at 24 hours (**Fig. 1B**) and type II *IFNG* at 6 and 10 hours by 88% and 83% (**Fig. 1C**), respectively, post stimulation in patient PBMCs compared to normal cells. Moreover, *ISG15* expression was significantly reduced at 6, 10 and 24 hours by 73%, 84%, and 68% (**Fig. 1D**), respectively, post transfection with poly(I:C) in patient compared to normal PBMCs. Nonetheless, *ISG15* transcript level was still significantly increased in stimulated patient PBMCs at 6, 10 and 24 hours compared to non-stimulated condition at 24 hours (**Fig. 1D**).

These results suggest that the function of the putatively truncated form of MDA5 appears to be disrupted based on the decrease in the expression of type I *IFNA*, and type II *IFNG* and interferon-stimulated gene *ISG15*.




Figure 1: Decreased levels of *IFNA*, *IFNG*, and *ISG15* transcripts in peripheral blood mononuclear cells with p.D673Ifs*5 MDA5 truncation. (A) A scheme presenting the domains of the full length MDA5 protein versus the potential truncated from of IFIH1 c.del2016A. CARDS: Caspase Activation and Recruitment Domains, DEXDc: DEAD and DEAH box helicase domain, HELICc: Helicase C Domain, CTD: C-terminal domain-like regions. Normal PBMCs (nPBMC) and patient 4 PBMCs (P4 PBMC) were transfected poly(I:C) for 6, 10, and 24 hours. Transfected cells without poly(I:C) were collected after 24 hours. RT-qPCR for *IFNA*, *IFNG* and *ISG15* expression was performed and normalized to

GAPDH. The results are expressed as percentage of treated nPBMC (\pm) SD for (A) *IFNA*, (B) *IFNG* and (C-left panel) *ISG15*. The results are expressed as percentage of untreated nPBMC (\pm) SD for (C-middle panel) *ISG15* and untreated P4 PBMC for (C-right panel) *ISG15*. The student's t-test was performed to validate significance. *, **, and *** indicate p-values \leq 0.05; 0.01; and 0.001, respectively.

Discussion

Autoinflammation, chronic inflammation, autoimmunity, and high susceptibility to microbial infections are signs of immune dysregulation, caused by environmental triggers, genetic predisposition, or infections³³. Mutations in the pathogen recognition receptors, which are responsible for detection of microbial components, alter the innate immune response, hence inducing either an inadequate or self-targeted immunity. MDA5 is an essential innate RIG-1-like receptor that mounts a type 1 innate immune response against viral infections. Genetic alterations of MDA5 leading to loss- or gain-of-function are translated to a wide range of immune diseases. In our study, we highlighted the consequences of *IFIH1* putative loss-of-function variants in altering the immune response and predisposing patients to viral infections like SARS-CoV-2, inflammation, and immune-related disorders.

In this study, we showed that six different *IFIH1* variants were detected in nine patients suffering from severe COVID-19, MIS-C, periodic fever, inflammatory bowel disease, or immunodeficiency with glomerulonephritis. Interestingly, different patients with varied *IFIH1* heterozygous variants had the same clinical manifestation, while the same variant showed different clinical outcomes in different patients. This illustrates the complex phenotypic and genotypic heterogeneity in *IFIH1* related disorders, though environmental factors as well as the genetic background of the patients may also have contributed to the difference in clinical symptoms.

One of the disorders in our cohort is glomerulonephritis, which is the main cause of end-stage and chronic kidney diseases. Susceptibility loci in innate immune genes like *IRF4* and *NFKB1* were related to membrane nephropathy³⁴. Herein, one patient had a homozygous *IFIH1* variant, c.2807+1G>A, leading to immunodeficiency with glomerulonephritis. This case was the most severe compared to other cases with heterozygous variants of *IFIH1*, emphasizing the dosage effect on the severity of symptoms and predisposition to diseases.

Periodic fever syndromes are a spectrum of disorders caused by pathogenic variants of the inflammasome and other innate immune related proteins³⁵. These include Familial

Mediterranean fever gene (*MEFV*)^{36,37}, NLR family pyrin domain containing 3 (*NLRP3*)³⁸, tumor necrosis factor receptor superfamily 1A (*TNFRSF1A*)³⁹, and others. Herein, patients # 1, 2, and 3 with periodic fever were associated with *IFIH1* heterozygous variants. The observation that patients had low lymphocyte count, lymphopenia, and increased Amyloid A suggests that the above variants contribute to chronic inflammation due to chronic infection or autoimmunity hence leading to periodic fever.

MDA5 is known to be essential in inducing antiviral type I and III interferons against SARS-CoV-2 virus⁴⁰. Thus, the severity of the coronavirus disease, COVID-19, is inversely correlated with type I interferon produced upon MDA5 activation⁴¹. In our study, we reported two cases with severe COVID-19 and the *IFIH1* putative loss-of-function variants c.1641+1G>C and c.2730C>A, which are likely to impair MDA5 activation, hence disrupting type I interferon activity and reducing viral clearance leading to severe COVID-19 outcomes.

In a recent study, a patient identified with very early onset inflammatory bowel disease was characterized with a homozygous variant in *IFIH1* (c.2016delA). The resulting truncated MDA5 (p.D673Ifs*5) receptor, lack Hel2, Pincer, and CTD domains. As a result, the patient suffered from multiple viral and bacterial infection leading to sepsis²⁰. Herein, we identify this variant in the heterozygous state in two patients (patients #4 and #7) who presented with different clinical consequences, multisystem inflammatory syndrome in children (MIS-C) and inflammatory bowel disease, respectively²⁴. IBD is a consequence of altered immunity towards certain bacterial species and viruses in the gastrointestinal tract which causes inflammation⁴². Patients with homozygous *IFIH1* variant were found to be subjected to bacterial superinfections^{13,14}. MDA5 has been proposed to play a role in the activation of immunological responses during bacterial septicemia⁴³. Indeed, Li *et al.* illustrated that RLR/MAVS pathway is activated by commensal bacterial RNA and hence modulates the mucosal immunity towards various microbes in the intestine⁴⁴. As such, MDA5 dysregulation can be linked to inflammatory bowel disease.

In our study the *IFIH1* c.2016delA;p.D673Ifs*5 variant, associated with IBD in this (patient #7) and previous studies, was intriguingly present in patient #4 who was diagnosed with MIS-C. Our expression analysis showed that type I interferon (*IFNA*), type II interferon (*IFNG*), and interferon stimulated genes (*ISG15*) transcript levels were significantly reduced in PBMCs of this patient compared to wild type upon stimulation with poly(I:C) at different time points. Cananzi *et al.* showed that the homozygous p.D673Ifs*5 variant impairs MDA5

ability to activate the *IFNB1* promoter, implying a complete loss-of-function that might result in type I interferon reduction²⁰. In addition, deletion or silencing of RIG-1-like receptors (MDA5, LGP2) in iPSC-derived airway epithelium or non-small-cell lung cancer cells led to a decrease in type I IFN expression upon SARS-CoV-2 infection^{45,46}.

Studies have highlighted that *ISG15* expression, an ubiquitin-like protein (Ubl), can be induced by type I IFN (IFN- α/β) in a dependent^{47,48} and independent manner prompted by other immune activators^{49,50}. Heat-killed Salmonella and poly(I:C) were shown to induce *ISG15* expression in a type I IFN-dependent manner⁴⁸, which explains the reduction in *ISG15* expression in our study. In the non-canonical pathway, extracellular ISG15 binds LFA-1 (Lymphocyte function-associated antigen 1) on surface of lymphocytes, especially NK cell, thereby inducing IFN- γ secretion^{48,51,52}. Binding LFA-1 augments IFN- γ as well as other pro-inflammatory cytokines secretion including, IL-1, IL-6, CXCL1 and CXCL5, in addition to an anti-inflammatory cytokine, IL10^{51,53}. Hence, the reduction in *IFNG* expression can be linked to the decrease in *ISG15* due to *IFIH1* loss-of-function. On the contrary, infection with SARS-CoV-2 does not only implicate MDA5, but is associated with multiple inflammatory pathways activation causing hyperinflammation and a cytokine storm⁵⁴. Indeed, patient #4 suffered from hyperinflammation which suggests another source of pro-inflammatory cytokine secretion rather than activated MDA5 receptor. In addition, the patient had lymphopenia which might be related to IFNG levels as IFN- γ was shown to mediate lymphocyte and monocyte recruitment to the site of infection^{55,56}. Overall, MDA5 dysregulation might lead to the disruption of innate and adaptive immune responses against infections.

In an antiviral defence mechanism, ISG15 induces the ISGylation of certain host and pathogenic proteins inhibiting several viral infections including but not limited to influenza A, HIV, Zika, hepatitis B and C⁵⁷. ISGylation of the viral sensor MDA5 caspase CARDs at Lys23 and Lys43 allow its oligomerization, thus leading to its activation⁵⁸. This activation initiates the antiviral innate immune response that act against a wide range of viruses such as coronaviruses, picornaviruses, and flaviviruses⁵⁸. Conversely, viruses deubiquitinate central signaling proteins like TBK1, I κ B α , IKK, RIG-I, and MAVS, via viral deubiquitinating enzymes (DUBs) that might target ISGylation as well to combat immunity⁵⁹⁻⁶¹. Coronaviruses are capable of suppressing IFN-mediated antiviral responses, where low IFN levels in SARS-CoV-2-infected patients were associated with severe disease⁶². Moreover, MDA5 ISG15-activation was shown to be antagonized via de-ISGylation by a papain-like

protease (PLpro) of SARS-CoV-2⁵⁸. Herein, our results show a significant increase in ISG15 transcript level in poly (I:C) stimulated PBMCs carrying the putative p.D673Ifs*5 variant compared to non-stimulated cells, which might be explained by a possible translation of MDA5 wild-type form due to heterozygosity. Consequently, aiding in partial but not complete loss-of-function upon stimulation with poly(I:C). The increase in ISG15 in MDA5 mutant PBMCs can also suggest another source of immune activators^{49,50}. Nonetheless, this may not imply a partial activation of MDA5 in patient #4. As SARS-CoV-2 PLpro would de-ISGylate MDA5⁵⁸ leading to total functional impairment during infection. This might elucidate the severity of the MIS-C patients case possessing MDA5 mutation, especially that MDA5 is the main SARS-CoV-2 sensor in the lungs⁴⁶.

Additionally, children were observed to have higher expression of RIG-I, MDA5 and LGP2⁶³ which can be translated to a pre-activated innate immune response leading to an early onset of interferon production in children's infected airways^{63,64}. This allows a faster viral clearance and lower viral load compared to adults, which might explain the severity of SARS-CoV-2 infection in the MIS-C patient possessing a potential truncated form of MDA5, as these patients are vulnerable to viral infections.

Conclusion

Pathogenic loss-of-function *IFIH1* variants predispose patients to recurrent infections, autoinflammatory, and autoimmune disorders. Identifying MDA5 pathogenic variants and deciphering the mechanisms and downstream pathways for the initiation of MDA5-related disorder is essential for the development of targeted therapies and interventions to support the immune system in affected patients.

References

1. Dias Junior, A. G., Sampaio, N. G. & Rehwinkel, J. A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation. *Trends Microbiol* **27**, 75–85 (2019).

2. Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: their regulation and roles in RNA sensing. *Nat Rev Immunol* **20**, 537–551 (2020).
3. Brisse, M. & Ly, H. Comparative Structure and Function Analysis of the RIG-I-Like Receptors: RIG-I and MDA5. *Frontiers in Immunology* **10**, (2019).
4. Lee, H.-C., Chathuranga, K. & Lee, J.-S. Intracellular sensing of viral genomes and viral evasion. *Exp Mol Med* **51**, 1–13 (2019).
5. Kasumba, D. M. & Grandvaux, N. Therapeutic Targeting of RIG-I and MDA5 Might Not Lead to the Same Rome. *Trends Pharmacol Sci* **40**, 116–127 (2019).
6. Ori, D., Murase, M. & Kawai, T. Cytosolic nucleic acid sensors and innate immune regulation. *Int Rev Immunol* **36**, 74–88 (2017).
7. Rice, G. I. *et al.* Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. *Nat Genet* **46**, 503–509 (2014).
8. Oda, H. *et al.* Aicardi-Goutières syndrome is caused by IFIH1 mutations. *Am J Hum Genet* **95**, 121–125 (2014).
9. Rutsch, F. *et al.* A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome. *Am J Hum Genet* **96**, 275–282 (2015).
10. Van Eyck, L. *et al.* Brief Report: IFIH1 Mutation Causes Systemic Lupus Erythematosus With Selective IgA Deficiency. *Arthritis & Rheumatology* **67**, 1592–1597 (2015).
11. Ahmad, S. *et al.* Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation. *Cell* **172**, 797-810.e13 (2018).
12. Crow, Y. J. & Manel, N. Aicardi–Goutières syndrome and the type I interferonopathies. *Nat Rev Immunol* **15**, 429–440 (2015).
13. Lamborn, I. T. *et al.* Recurrent rhinovirus infections in a child with inherited MDA5 deficiency. *J Exp Med* **214**, 1949–1972 (2017).

14. Asgari, S. *et al.* Severe viral respiratory infections in children with IFIH1 loss-of-function mutations. *Proc Natl Acad Sci U S A* **114**, 8342–8347 (2017).
15. Zaki, M. *et al.* Recurrent and Prolonged Infections in a Child with a Homozygous IFIH1 Nonsense Mutation. *Front Genet* **8**, 130 (2017).
16. Enevold, C. *et al.* Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. *J Neuroimmunol* **212**, 125–131 (2009).
17. Smyth, D. J. *et al.* A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat Genet* **38**, 617–619 (2006).
18. Gorman, J. A. *et al.* The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity. *Nat Immunol* **18**, 744–752 (2017).
19. Ellinghaus, D. *et al.* Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat Genet* **48**, 510–518 (2016).
20. Cananzi, M. *et al.* +IFIH1 Loss-of-function variants contribute to Very Early Onset Inflammatory Bowel Disease. *Hum Genet* **140**, 1299–1312 (2021).
21. Fathalla, B. M., Alsarhan, A., Afzal, S., El Naofal, M. & Abou Tayoun, A. The genomic landscape of pediatric rheumatology disorders in the Middle East. *Human Mutation* **42**, e1–e14 (2021).
22. Jain, R. *et al.* Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes. *Computational and Structural Biotechnology Journal* **19**, 153–160 (2021).

23. Badla, B. A. *et al.* Genetic determinants of severe COVID-19 in young Asian and Middle Eastern patients. 2023.01.11.23284427 Preprint at <https://doi.org/10.1101/2023.01.11.23284427> (2023).
24. Abuhammour, W. *et al.* Genetic and Clinical Characteristics of Patients in the Middle East With Multisystem Inflammatory Syndrome in Children. *JAMA Network Open* **5**, e2214985 (2022).
25. El Naofal, M. *et al.* The genomic landscape of rare disorders in the Middle East. *Genome Medicine* **15**, 5 (2023).
26. Ramaswamy, S. *et al.* Middle Eastern Genetic Variation Improves Clinical Annotation of the Human Genome. *Journal of Personalized Medicine* **12**, 423 (2022).
27. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* **3**, 1101–1108 (2008).
28. Scott, E. M. *et al.* Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. *Nat Genet* **48**, 1071–1076 (2016).
29. Thorne, J. *et al.* Serum Amyloid A Protein-Associated Kidney Disease: Presentation, Diagnosis, and Management. *Kidney Med* **4**, 100504 (2022).
30. Saxena, R., Johansson, C., Bygren, P. & Wieslander, J. Autoimmunity and glomerulonephritis. *Postgrad Med J* **68**, 242–250 (1992).
31. Wen, Z. & Fiocchi, C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? *Clin Dev Immunol* **11**, 195–204 (2004).
32. Davitt, E. *et al.* COVID-19 disease and immune dysregulation. *Best Pract Res Clin Haematol* **35**, 101401 (2022).
33. Long, A., Kleiner, A. & Looney, R. J. Immune dysregulation. *Journal of Allergy and Clinical Immunology* **151**, 70–80 (2023).

34. Wu, M.-Y., Chen, Y.-C., Chiu, I.-J. & Wu, M.-S. Genetic insight into primary glomerulonephritis. *Nephrology* **27**, 649–657 (2022).
35. Hoang, T. K. & Albert, D. A. Novel presentations of periodic fever syndromes: Discrepancies between genetic and clinical diagnoses. *Eur J Rheumatol* **6**, 12–18 (2019).
36. Onen, F. Familial Mediterranean fever. *Rheumatol Int* **26**, 489–496 (2006).
37. Matsumoto, S., Urayoshi, S. & Yoshida, Y. Familial Mediterranean fever in which Crohn's disease was suspected: a case report. *BMC Res Notes* **7**, 678 (2014).
38. Baroja-Mazo, A. *et al.* The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. *Nat Immunol* **15**, 738–748 (2014).
39. Cantarini, L. *et al.* Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. *Autoimmun Rev* **12**, 38–43 (2012).
40. Sampaio, N. G. *et al.* The RNA sensor MDA5 detects SARS-CoV-2 infection. *Sci Rep* **11**, 13638 (2021).
41. Tonutti, A. *et al.* Anti-MDA5 Antibody Linking COVID-19, Type I Interferon, and Autoimmunity: A Case Report and Systematic Literature Review. *Frontiers in Immunology* **13**, (2022).
42. Zhang, L. *et al.* Bacterial Species Associated With Human Inflammatory Bowel Disease and Their Pathogenic Mechanisms. *Front Microbiol* **13**, 801892 (2022).
43. Asadpour-Behzadi, A. & Kariminik, A. RIG-1 and MDA5 are the important intracellular sensors against bacteria in septicemia suffering patients. *Journal of Applied Biomedicine* **16**, 358–361 (2018).
44. Li, X.-D. *et al.* Mitochondrial antiviral signaling protein (MAVS) monitors commensal bacteria and induces an immune response that prevents experimental colitis. *Proceedings of the National Academy of Sciences* **108**, 17390–17395 (2011).

45. Yin, X. *et al.* MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. *Cell Reports* **34**, (2021).
46. Rebendenne, A. *et al.* SARS-CoV-2 Triggers an MDA-5-Dependent Interferon Response Which Is Unable To Control Replication in Lung Epithelial Cells. *J Virol* **95**, e02415-20 (2021).
47. Farrell, P. J., Broeze, R. J. & Lengyel, P. Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. *Nature* **279**, 523–525 (1979).
48. Swaim, C. D. *et al.* Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins. *Cell Reports* **31**, 107772 (2020).
49. Ashley, C. L., Abendroth, A., McSharry, B. P. & Slobedman, B. Interferon-Independent Upregulation of Interferon-Stimulated Genes during Human Cytomegalovirus Infection is Dependent on IRF3 Expression. *Viruses* **11**, 246 (2019).
50. Lertsooksawat, W., Wongnoppavich, A. & Chairatvit, K. Up-regulation of interferon-stimulated gene 15 and its conjugation machinery, UbE1L and UbcH8 expression by tumor necrosis factor- α through p38 MAPK and JNK signaling pathways in human lung carcinoma. *Mol Cell Biochem* **462**, 51–59 (2019).
51. Swaim, C. D., Scott, A. F., Canadeo, L. A. & Huibregtse, J. M. Extracellular ISG15 Signals Cytokine Secretion Through the LFA-1 Integrin Receptor. *Mol Cell* **68**, 581-590.e5 (2017).
52. Recht, M., Borden, E. C. & Knight, E., Jr. A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. *The Journal of Immunology* **147**, 2617–2623 (1991).
53. dos Santos, P. F. *et al.* ISG15-Induced IL-10 Is a Novel Anti-Inflammatory Myeloid Axis Disrupted during Active Tuberculosis. *The Journal of Immunology* **200**, 1434–1442 (2018).

54. Tan, L. Y., Komarasamy, T. V. & RMT Balasubramaniam, V. Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. *Frontiers in Immunology* **12**, (2021).
55. Issekutz, T. B., Stoltz, J. M. & van der Meide, P. The recruitment of lymphocytes into the skin by T cell lymphokines: the role of gamma-interferon. *Clin Exp Immunol* **73**, 70–75 (1988).
56. Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K. & Oliveira, M. J. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. *Frontiers in Immunology* **9**, (2018).
57. Morales, D. J. & Lenschow, D. J. The Antiviral Activities of ISG15. *Journal of Molecular Biology* **425**, 4995–5008 (2013).
58. Liu, G. *et al.* ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. *Nat Microbiol* **6**, 467–478 (2021).
59. Bailey-Elkin, B. A., Knaap, R. C. M., Kikkert, M. & Mark, B. L. Structure and Function of Viral Deubiquitinating Enzymes. *Journal of Molecular Biology* **429**, 3441–3470 (2017).
60. Dackowski, C. M. *et al.* Structural Insights into the Interaction of Coronavirus Papain-Like Proteases and Interferon-Stimulated Gene Product 15 from Different Species. *Journal of Molecular Biology* **429**, 1661–1683 (2017).
61. Dzimianski, J. V. *et al.* Probing the impact of nairovirus genomic diversity on viral ovarian tumor domain protease (vOTU) structure and deubiquitinase activity. *PLoS Pathog* **15**, e1007515 (2019).
62. Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* **369**, 718–724 (2020).

63. Loske, J. *et al.* Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol* **40**, 319–324 (2022).
64. Lazova, S., Dimitrova, Y., Hristova, D., Tzotcheva, I. & Velikova, T. Cellular, Antibody and Cytokine Pathways in Children with Acute SARS-CoV-2 Infection and MIS-C—Can We Match the Puzzle? *Antibodies (Basel)* **11**, 25 (2022).